Navigation Links
New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Date:4/9/2008

Emerging Agent GlaxoSmithKline's Rezonic Demonstrating Efficacy for Delayed Chemotherapy-Induced Nausea and Vomiting, According to a New Report from

Decision Resources

WALTHAM, Mass., April 9, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the regimen of Merck's Emend for Injection/Ivemend combined with 5-HT3 RA, is positioned to earn gold-standard status in the treatment of chemotherapy-induced nausea and vomiting by 2011. The regimen of Emend for Injection/Ivemend and 5-HT3 RA offers robust efficacy and key advantages in delivery as a result of its availability in a single-dose IV formulation that is more convenient than the three-consecutive-day-dosing schedule of Merck's Emend, the current gold standard.

The new report entitled Chemotherapy-Induced Nausea and Vomiting: Physician Satisfaction with Inexpensive Antiemetics Sets High Hurdles for Reformulations and Emerging Agents, also finds that GlaxoSmithKline's Rezonic, launching in 2009 as the second-to-market NK1 RA, is positioned as the only emerging agent, compared with Emend, with the potential to demonstrate better control over delayed chemotherapy-induced nausea and vomiting in patients taking highly emetogenic chemotherapy. Preliminary data from clinical trials show that the addition of oral Rezonic to GlaxoSmithKline's Zofran and Merck/Banyu's Decadron result in an 86 percent of patients with no emetic episodes and do not require rescue therapy compared with Emend's 68 percent; however, more data is needed to confirm the effect on delayed chemotherapy-induced nausea and vomiting. Additionally, unless Rezonic shows extraordinary efficacy or is priced much lower than currently available NK1 antagonists, it is not expected to gain more patient share than the Emend franchise owing to Emend's first-to-market status in the injectable NK1 antagonist class.

<
'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... OSTE ), a leader in the emerging ... that it has received 510(k) clearance,from the United ... next,generation grafting material. Osteotech received 510(k) clearance for ... a bone void filler, for use in,the spine, ...
... the way Misukanis & Odden schedule tasks. , ... ... ), creators of the ground breaking OnePlace Chaos Management ... series "A Day In The Life." The newest level of project ...
... gains derived from the use of nanomaterials may be ... them. Research published in a special issue of ... journal owned by Yale University and headquartered at the ... need for improved efficiency in the manufacturing of nanoscale ...
Cached Biology Technology:Osteotech Receives FDA Clearance for its Next Generation Grafting Material 2Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles 2Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles 3A need for improved efficiency in nanomanufacturing 2
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/12/2014)... GARDENS, Fla. , Nov. 12, 2014 ... announced today that its U.are.U ® fingerprint readers ... bakery chain in Central Mexico . ... June 2014 to eliminate payroll issues caused by employees ... to installing the U.are.U fingerprint readers, Montparnasse relied on ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Louis, Oct.20, 2008 Researchers have shown that self-induced breaks ... genes that cause the cells to travel from where they,re ... Scientists have known for two decades or more that ... splits in both of the two strands. However, the new ...
... people trying to help nature by,designing corridors for wildlife ... to think in terms of regular, symmetrical,structures, but nature ... Matthew Holland, the study,s lead author. "We,found that symmetrical ... communities than designs with some randomness or,asymmetry built in." ...
... OCTOBER 20, 2008 -- The widespread use of pesticides across ... little knowledge of the long-term effects on the nation,s groundwater. ... that samples taken from over 300 wells across the US ... news is a result of a decadal long study to ...
Cached Biology News:Seemingly suicidal stunt is normal rite of passage for immune cells 2Seemingly suicidal stunt is normal rite of passage for immune cells 3Pesticide concentrations decreasing 2
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Biology Products: